IT’S the quintessential image of a Scotsman and the perfect way to stand out from the crowd. However, concern has been raised by the boss of a Glasgow firm that a lack of information is preventing the kilt being hired by ex pats living in the European Union. Michael Dalrymple, owner of A1 Kilt Hire in the city’s north, said little clarity over the cost of tax post-Brexit on goods into the block has made it impossible to price items. Mr Dalrymple said: “We have the demand and the product but what we do not have is information.
Jan 18 2021 Read 3347 Times
Funding of £2.5 million is being invested in a COVID-19 drug screening and resistance hub at the MRC-University of Glasgow Centre for Virus Research (CVR) in partnership with medical research charity LifeArc, which has donated £2 million and the MRC which has provided additional funding.
The ground-breaking project, CRUSH (COVID-19 Drug-Screening and Resistance Hub), dedicated to supporting global scientific effort and accelerating vital COVID-19 antiviral innovation drug translation, will be delivered by the partners and the University of Dundee Drug Discovery Unit.
Professor Massimo Palmarini, Director of the CVR, said: “The establishment of CRUSH is an exciting development for the CVR and we are delighted to be partnering with LifeArc on this initiative.
Screening and Resistance
Hub), has received £2.5million to establish a national resource which will initially be dedicated to supporting and accelerating vital COVID-19 antiviral innovation drug translation.
The facility is funded by £2m from medical research charity LifeArc, with additional funding from the Medical Research Council. CVR CRUSH will be delivered by the University of Glasgow in collaboration with partners LifeArc and the University of Dundee Drug Discovery Unit.
Global control of the COVID-19 pandemic is dependent on the availability of effective medical treatments and vaccines. CVR CRUSH will help support the global scientific effort against the disease by providing a fully integrated hub for pre-clinical drug screening and resistance assays for SARS-CoV-2, the virus that causes COVID-19, as well as providing the same services for other dangerous and deadly viruses in high containment facilities.
New COVID-19 drug screening hub established in Scotland
7th January 2021
A new COVID-19 drug screening and resistance facility, funded by medical research charity LifeArc, has been established at the MRC-University of Glasgow Centre for Virus Research (CVR).
The project – COVID-19 Drug-Screening and Resistance Hub (CRUSH) – has been granted £2.5m to establish a hub dedicated to supporting and accelerating COVID-19 antiviral innovation drug translation.
It is funded by £2m from LifeArc plus additional funding from the Medical Research Council, with the hub set to be delivered by the University of Glasgow in Collaboration with LifeArc and the University of Dundee Drug Discovery Unit.
Glasgow University science hub established to screen Covid-19 drugs
A coronavirus sample is held at a laboratory in Glasgow (Andrew Milligan/PA)
A £2.5 million science hub is to be established at the University of Glasgow to screen treatments for Covid-19.
Crush (Covid-19 Drug-Screening and Resistance Hub) will investigate promising drugs for the virus.
It will also provide drug screening for other dangerous and deadly viruses in its high containment facilities.
Scientists at the hub will look to identify any possible drug and immune-resistant virus variants.
Research charity LifeArc has given £2 million to the project, with additional funds provided by the Medical Research Council.